JosephPHorriganMDFAACAP
Psychiatry • Research Triangle Park, NCChild & Adolescent Psychiatry
Physician
Dr. Horrigan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Five Moore Drive
Research Triangle Park, NC 27709Phone+1 919-483-7942Fax+1 919-483-8302
Education & Training
University of North Carolina HospitalsFellowship, Child and Adolescent Psychiatry, 1991 - 1994- University of North Carolina HospitalsResidency, Psychiatry, 1988 - 1991
University of Rochester School of Medicine and DentistryClass of 1988
Certifications & Licensure
CA State Medical License 1998 - 2026
ME State Medical License 2021 - 2026
MA State Medical License 1994 - 2025
NC State Medical License 1990 - 2025
RI State Medical License 1999 - 1999- American Board of Psychiatry and Neurology Psychiatry
- American Board of Psychiatry and Neurology Child & Adolescent Psychiatry
Clinical Trials
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Start of enrollment: 2010 Apr 01
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC Start of enrollment: 2013 Feb 01
- A Safety Study of NNZ-2566 in Patients With Rett Syndrome Start of enrollment: 2013 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 37 citationsA Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)Joseph P. Horrigan, Tiago Gomes, Mike Snape, Nikoletta Nikolenko, Alison McMorn
Pediatric Neurology. 2020-11-01 - 25 citationsAdjunctive Maintenance Lamotrigine for Pediatric Bipolar i Disorder: A Placebo-Controlled, Randomized Withdrawal StudyRobert L. Findling, Kiki D. Chang, Adelaide S. Robb, Vicki J. Foster, Joseph P. Horrigan
Journal of the American Academy of Child and Adolescent Psychiatry. 2015-12-01 - 110 citationsBupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled studyTimothy E. Wilens, Barbara R. Haight, Joseph P. Horrigan, James J. Hudziak, Norman E. Rosenthal
Biological Psychiatry. 2005-04-01
Press Mentions
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic DystrophyDecember 22nd, 2021- AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic DystrophyMay 17th, 2021
- AMO Pharma to Participate in Myotonic Dystrophy Foundation "Meet the DM Drug Developers" Program on March 5, 2021March 3rd, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Member
- Member
- International Society for Autism ResearchMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
